跳至主要内容
临床试验/2023-509675-16-01
2023-509675-16-01招募中3 期

Reduced anticoagulation targets in extracorporeal life support

Universitair Medisch Centrum Groningen7 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2025年1月28日最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
330
试验地点
7
主要终点
The primary outcome parameter is a combined endpoint consisting of: 1) major bleeding including hemorrhagic stroke according to the ELSO definitions; 2) severe thromboembolic complication defined as ischemic stroke, limb ischemia (not related with distal perfusion catheter), or acute pump failure with emergency exchange; 3) mortality at 6 months.

研究概览

简要总结

Our primary research question is if anticoagulation with UFH with reduced anticoagulation targets or anticoagulation with low molecular weight heparin (LMWH) leads to a reduction in the occurrence of major bleeding without an increase in thromboembolic complications or a negative effect on outcome compared to the standard practice of high anticoagulation targets with UFH. We expect fewer complications and improvement of survival after ECMO therapy for both interventions.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • All adults receiving ECMO treatment at the ICU of one of the participating centers during the study period are eligible for inclusion.

排除标准

  • The exclusion criteria are as follows: (1) patients in whom the ECMO is only used to bridge a procedure like a high-risk percutaneous coronary intervention or during surgery; (2) no (deferred) informed consent; (3) vital indication for robust anticoagulation (e.g., mechanic mitral valve, pulmonary embolism, a clot in the cardiac ventricle); and (4) a history of heparin-induced thrombocytopenia (HIT).

结局指标

主要结局

The primary outcome parameter is a combined endpoint consisting of: 1) major bleeding including hemorrhagic stroke according to the ELSO definitions; 2) severe thromboembolic complication defined as ischemic stroke, limb ischemia (not related with distal perfusion catheter), or acute pump failure with emergency exchange; 3) mortality at 6 months.

The primary outcome parameter is a combined endpoint consisting of: 1) major bleeding including hemorrhagic stroke according to the ELSO definitions; 2) severe thromboembolic complication defined as ischemic stroke, limb ischemia (not related with distal perfusion catheter), or acute pump failure with emergency exchange; 3) mortality at 6 months.

次要结局

  • Secondary outcome parameters are: 1) blood transfusions; 2) health related quality of life (HR-QoL) at 6 months; 3) exchange of the membrane oxygenator; 4) vessel thrombosis after ECMO removal detected by echography; 5) pulmonary embolism; 6) costs; 7) the individual components of the composite outcome; and 8) all thromboembolic complications combined.

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Walter M. van den Bergh

Scientific

Universitair Medisch Centrum Groningen

研究点 (7)

Loading locations...

相似试验